M Pharmaceutical Inc. Announces the Successful Design and Engineering of Their Unique “Sequential Release Dual Compartment Gelatin Capsule” Required for the Effective Delivery of C-103, Re-Formulated Orlistat

VANCOUVER, BC / ACCESSWIRE / August 16, 2016 / M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “M Pharma”), announced today that it has successfully completed the design and engineering of a sequential release dual compartment gelatin capsule (“Sequential Capsule”) for its re-formulated C-103 project.

C-103 is a patented, proprietary combination of orlistat, simethicone and activated charcoal, which is designed to maintain the efficacy of orlistat while minimizing its bowel-related side effects. The drugs are not systemically absorbed, and all are approved by the FDA for OTC usage and have strong safety profiles.

In order to commercialize C-103, M Pharmaceutical USA Inc. has been focused on formulating these technologies into one Sequential Capsule that maintains the efficacy of orlistat, but without the adverse events.

The benefits of the new capsule design include:

The release of three separate ingredients in a designed sequence while the capsule travels the digestive tract in order to gain the most effective result;
A series of sophisticated manufacturing techniques that will be considered proprietary;
The proprietary manufacturing process provides an additional level of global patent protection.

“Recognizing that the development of C-103 hinged on the engineering of a sophisticated delivery system, this is a very significant achievement toward the successful commercialization of our C-103 project,” said Gary Thompson, President of M Pharmaceutical USA Inc. “Designing this unique and innovative sequential release delivery system was a complex process, but its success adds significant momentum to our goal of marketing our proprietary, re-formulated orlistat drug technology. This new design means we can engage immediately with prospective capsule manufacturing partners, allowing us to advance to clinical trials and commercialization.”

To view the graphic, please click here

C-103 is a novel formulation of orlistat, patented until 2030 in the United States. Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter). Orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007. C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable side effects.

About M Pharmaceutical Inc.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of Orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights.

M Pharmaceutical Inc. trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”

For more information contact:

Investor Relations
Phone: +1 604 428 0511
info@m-pharma.ca
www.m-pharma.ca

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the company’s biomedical and drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

SOURCE: M Pharmaceutical Inc.

ReleaseID: 443816